1620675-68-4

Usage

Uses

Used in Medicinal Chemistry:
(6S,8aR)-3-oxooctahydroindolizine-6-carboxylic acid is used as a compound of interest in medicinal chemistry due to its unique structure and functional groups that may allow for interactions with biological systems. (6S,8aR)-3-oxooctahydroindolizine-6-carboxylic acid is currently under investigation for its potential therapeutic properties and pharmacological activities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (6S,8aR)-3-oxooctahydroindolizine-6-carboxylic acid is used as a subject of research for its potential therapeutic applications. Ongoing studies aim to explore the compound's biological and pharmacological activities, with the goal of identifying its possible uses in the development of new medications.
Used in Drug Design and Development:
(6S,8aR)-3-oxooctahydroindolizine-6-carboxylic acid is utilized as a structural template in drug design and development. Its unique bicyclic structure and functional groups may serve as a foundation for creating new drugs with specific targeting capabilities or improved pharmacological profiles.

Upstream product

• 1620675-65-1 methyl 3-oxooctahydroindolizine-6-carboxylate 
• 1620675-64-0 methyl 6-(3-ethoxy-3-oxopropyl)piperidine-3-carboxylate 
• 1620675-63-9 (E)-methyl 6-(3-ethoxy-3-oxoprop-1-en-1-yl)nicotinate 
• 5470-70-2 Methyl 6-methylnicotinate 

Relevant academic research and scientific papers

BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.